Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.59 |
| ▸ | CTSK | P43235 | 6/20 | 0.59 |
| ▸ | MME | P08473 | 5/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895414 | 1.00 | CTSS (0.59) | CTSSCTSKMMEATMMMEL1 | |
| SCHEMBL4899560 | 1.00 | CTSS (0.59) | CTSSCTSKMMEATMMMEL1 | |
| SCHEMBL28132845 | 0.88 | ATM (0.60) | CTSSCTSKMMEATMAPP | |
| SCHEMBL1519889 | 0.88 | ATM (0.56) | CTSSCTSKMMEATMAPP | |
| SCHEMBL29163523 | 0.88 | ATM (0.56) | CTSSCTSKMMEATMAPP | |
| SCHEMBL7897952 | 0.88 | ATM (0.56) | CTSSCTSKATMAPPACE | |
| SCHEMBL489489 | 0.88 | ATM (0.70) | CTSSCTSKATMAPPACE | |
| SCHEMBL1519945 | 0.88 | ATM (0.70) | CTSSCTSKATMAPPACE | |
| SCHEMBL489490 | 0.88 | ATM (0.70) | CTSSCTSKATMAPPACE | |
| SCHEMBL31494614 | 0.87 | CTSS (0.54) | CTSSCTSKMMEATMAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486762-A | Novel compound and use method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-02 | — | — | CN | disclosed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-7897619-B2 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2173728-A2 | HETEROCYCLIC MODULATORS OF PKB | Amgen Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009011880-A2 | HETEROCYCLIC MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275592-A1 | Heterocyclic modulators of PKB | MTOR, PDK1, EIF4EBP1 | CTSS 3165/4885CTSK 2241/4885MME 4797/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | CTSS 3395/4885CTSK 990/4885MME 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.